Related Experiment Video
Updated: Aug 6, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
1Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA; Department of Ophthalmology, Yale University School of Medicine, New Haven, CT, USA.
Abstract:
Song and Chow demonstrate that while tumor-intrinsic mutations in the IFN-γ signaling pathway confer immune resistance across in vitro co-culture systems, such alterations associate with enhanced anti-tumor immunity in vivo and improved responsiveness to immune checkpoint blockade therapy in patients with cancer.
Insights
Tumor mutations in the interferon-gamma (IFN-γ) signaling pathway cause immune resistance in lab tests. However, these mutations enhance anti-tumor immunity and improve responses to cancer immunotherapy in living organisms.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Tumor-intrinsic mutations in the interferon-gamma (IFN-γ) signaling pathway are known to confer immune resistance in in vitro co-culture systems.
- Understanding the in vivo implications of these mutations is crucial for developing effective cancer immunotherapies.
Discussion:
- This study reveals a paradoxical role of IFN-γ pathway mutations, demonstrating their association with enhanced anti-tumor immunity in vivo.
- These findings challenge the conventional view of immune resistance conferred by such mutations.
Key Insights:
- Tumor-intrinsic mutations in the IFN-γ signaling pathway are linked to improved anti-tumor immunity in vivo.
- Patients with these mutations show enhanced responsiveness to immune checkpoint blockade therapy.
- This suggests a potential predictive biomarker for immunotherapy response.
Outlook:
- Further research should explore the precise mechanisms driving enhanced in vivo immunity despite in vitro resistance.
- Investigating the therapeutic potential of targeting or leveraging these mutations in cancer treatment is warranted.
- These insights could pave the way for personalized immunotherapy strategies in oncology.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
10:10Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Related Concept Videos
Tumor Immunotherapy
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...